These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Lipid lowering in primary prevention: time to focus on young patients. Hayek A; Marquis-Gravel G Heart; 2023 Mar; 109(7):500-501. PubMed ID: 36446544 [No Abstract] [Full Text] [Related]
64. RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer. Harborg S; Cronin-Fenton DP; Borgquist S Breast Cancer Res Treat; 2019 Oct; 177(3):771-772. PubMed ID: 31270762 [No Abstract] [Full Text] [Related]
65. Lipid lowering in primary prevention: The lower is better, but where to settle? Yang WS J Formos Med Assoc; 2022 Dec; 121(12):2376-2377. PubMed ID: 35660117 [No Abstract] [Full Text] [Related]
66. Exploring New Combination Strategy of Lipid-Lowering Therapies for Primary Prevention of Cardiovascular Disease. Cho JH; Cho EJ; Jeong YH Korean Circ J; 2024 Sep; 54(9):545-548. PubMed ID: 39195196 [No Abstract] [Full Text] [Related]
67. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors. Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360 [TBL] [Abstract][Full Text] [Related]
68. A systematic review to assess adherence and persistence with statins. Deshpande S; Quek RG; Forbes CA; de Kock S; Kleijnen J; Gandra SR; Simpson RJ Curr Med Res Opin; 2017 Apr; 33(4):769-778. PubMed ID: 28076703 [TBL] [Abstract][Full Text] [Related]
69. Kent ST; Rosenson RS; Avery CL; Chen YI; Correa A; Cummings SR; Cupples LA; Cushman M; Evans DS; Gudnason V; Harris TB; Howard G; Irvin MR; Judd SE; Jukema JW; Lange L; Levitan EB; Li X; Liu Y; Post WS; Postmus I; Psaty BM; Rotter JI; Safford MM; Sitlani CM; Smith AV; Stewart JD; Trompet S; Sun F; Vasan RS; Woolley JM; Whitsel EA; Wiggins KL; Wilson JG; Muntner P Circ Cardiovasc Genet; 2017 Aug; 10(4):e001632. PubMed ID: 28768753 [TBL] [Abstract][Full Text] [Related]
70. Primary Care Physician Perspectives on Barriers to Statin Treatment. Tanner RM; Safford MM; Monda KL; Taylor B; O'Beirne R; Morris M; Colantonio LD; Dent R; Muntner P; Rosenson RS Cardiovasc Drugs Ther; 2017 Jun; 31(3):303-309. PubMed ID: 28710589 [TBL] [Abstract][Full Text] [Related]
71. Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014. Rosenson RS; Farkouh ME; Mefford M; Bittner V; Brown TM; Taylor B; Monda KL; Zhao H; Dai Y; Muntner P J Am Coll Cardiol; 2017 Jun; 69(22):2696-2706. PubMed ID: 28571633 [TBL] [Abstract][Full Text] [Related]
72. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. Colantonio LD; Huang L; Monda KL; Bittner V; Serban MC; Taylor B; Brown TM; Glasser SP; Muntner P; Rosenson RS JAMA Cardiol; 2017 Aug; 2(8):890-895. PubMed ID: 28423147 [TBL] [Abstract][Full Text] [Related]
73. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797 [TBL] [Abstract][Full Text] [Related]
77. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study. Aguiar C; Araujo F; Rubio-Mercade G; Carcedo D; Paz S; Castellano JM; Fuster V J Health Econ Outcomes Res; 2022; 9(2):134-146. PubMed ID: 36475278 [No Abstract] [Full Text] [Related]
78. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective. Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312 [TBL] [Abstract][Full Text] [Related]
79. Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia. Alghamdi A; Balkhi B; Altowaijri A; Al-Shehri N; Ralph L; Marriott ER; Urbich M; Aljanad F; Aziziyeh R Pharmacoecon Open; 2022 Mar; 6(2):277-291. PubMed ID: 34582002 [TBL] [Abstract][Full Text] [Related]
80. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease. Zhou T; Chen Z; Li H; Xie F Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]